Selling, General, and Administrative Costs: AbbVie Inc. vs HUTCHMED (China) Limited

A Tale of Two Companies: AbbVie Inc. vs. HUTCHMED (China) Limited

In the ever-evolving pharmaceutical industry, understanding the financial dynamics of major players is crucial. Over the past decade, AbbVie Inc. and HUTCHMED (China) Limited have showcased contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, AbbVie Inc. has seen a staggering 66% increase in SG&A costs, peaking in 2022. This reflects its aggressive expansion and marketing strategies. In contrast, HUTCHMED's SG&A expenses, though significantly smaller, have grown by approximately 400% over the same period, indicating its rapid scaling efforts in the competitive Chinese market. While AbbVie's expenses dwarf those of HUTCHMED, the latter's growth rate is noteworthy. This comparison highlights the diverse strategies and market challenges faced by pharmaceutical giants in different regions.